KU-5039

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameKU-5039

Drug Alias NameKU-5039

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAdenylate kinase 2 stimulantsProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsAdenylate kinase 1 stimulants +[4]

TargetsAdenylate kinase 2Protein kinase AMP-activated non-catalytic subunit beta 1Adenylate kinase 4 +[4]

Therapy Area/IndicationsInsulin ResistanceDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesKareus Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesKareus Therapeutics

Inactive CompaniesN/A

Active IndicationsInsulin ResistanceDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A